{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:43:07Z","timestamp":1794663787879,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Central nervous system (CNS) involvement remains a challenge in the diagnosis and treatment of acute lymphoblastic leukemia (ALL). In this study, we identify CD79a (also known as Ig\u03b1), a signaling component of the preB cell receptor (preBCR), to be associated with CNS-infiltration and \u2013relapse in B-cell precursor (BCP)-ALL patients. Furthermore, we show that downregulation of CD79a hampers the engraftment of leukemia cells in different murine xenograft models, particularly in the CNS.<\/jats:p>","DOI":"10.1038\/s42003-020-01591-z","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:02:30Z","timestamp":1610708550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"4","author":[{"given":"Lennart","family":"Lenk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Carlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Vogiatzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Spory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Winterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1516-2515","authenticated-orcid":false,"given":"Antony","family":"Cousins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Vossen-Gajcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olta","family":"Ibruli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vokuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El Ayoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ritgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"H\u00e4sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-2565","authenticated-orcid":false,"given":"Stephan","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5449-5246","authenticated-orcid":false,"given":"Christina","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1773-7677","authenticated-orcid":false,"given":"Irmela","family":"Jeremias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hobeika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-141X","authenticated-orcid":false,"given":"Hassan","family":"Jumaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-9890","authenticated-orcid":false,"given":"Ameera","family":"Alsadeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0217","authenticated-orcid":false,"given":"Denis M.","family":"Schewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","volume":"9","author":"C-H Pui","year":"2008","unstructured":"Pui, C.-H. & Howard, S. C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 9, 257\u2013268 (2008).","journal-title":"Lancet Oncol."},{"key":"1591_CR2","doi-asserted-by":"publisher","first-page":"e180089","DOI":"10.1001\/jamaoncol.2018.0089","volume":"4","author":"YT Cheung","year":"2018","unstructured":"Cheung, Y. T. et al. Association of cerebrospinal fluid biomarkers of central nervous system injury with neurocognitive and brain imaging outcomes in children receiving chemotherapy for acute lymphoblastic leukemia. JAMA Oncol. 4, e180089 (2018).","journal-title":"JAMA Oncol."},{"key":"1591_CR3","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/leu.2009.42","volume":"23","author":"S Jeha","year":"2009","unstructured":"Jeha, S. et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)\/TCF3-PBX1. Leukemia 23, 1406\u20131409 (2009).","journal-title":"Leukemia"},{"key":"1591_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/blood-2014-06-583062","volume":"125","author":"S Krause","year":"2015","unstructured":"Krause, S. et al. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS). Blood 125, 820\u2013830 (2015).","journal-title":"Blood"},{"key":"1591_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2016.147744","volume":"102","author":"A Alsadeq","year":"2017","unstructured":"Alsadeq, A. et al. The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. Haematologica 102, 346\u2013355 (2017).","journal-title":"Haematologica"},{"key":"1591_CR6","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood-2018-04-844209","volume":"132","author":"A Alsadeq","year":"2018","unstructured":"Alsadeq, A. et al. IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 132, 1614\u20131617 (2018).","journal-title":"Blood"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","volume":"19","author":"RR Hardy","year":"2001","unstructured":"Hardy, R. R. & Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 19, 595\u2013621 (2001).","journal-title":"Annu. Rev. Immunol."},{"key":"1591_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri2491","volume":"9","author":"S Herzog","year":"2009","unstructured":"Herzog, S., Reth, M. & Jumaa, H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9, 195\u2013205 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1591_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nri3487","volume":"13","author":"RC Rickert","year":"2013","unstructured":"Rickert, R. C. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat. Rev. Immunol. 13, 578\u2013591 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1591_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10555-020-09848-z","volume":"39","author":"L Lenk","year":"2020","unstructured":"Lenk, L., Alsadeq, A. & Schewe, D. M. Involvement of the central nervous system in acute lymphoblastic leukemia. Opinions on molecular mechanisms and clinical implications based on recent data. Cancer Metastasis Rev. 39, 173\u2013187 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"1591_CR11","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/blood-2015-08-665034","volume":"127","author":"MTS Williams","year":"2016","unstructured":"Williams, M. T. S. et al. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood 127, 1998\u20132006 (2016).","journal-title":"Blood"},{"key":"1591_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccell.2015.02.003","volume":"27","author":"H Geng","year":"2015","unstructured":"Geng, H. et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell 27, 409\u2013425 (2015).","journal-title":"Cancer Cell"},{"key":"1591_CR13","doi-asserted-by":"publisher","first-page":"13789","DOI":"10.1073\/pnas.0605944103","volume":"103","author":"E Hobeika","year":"2006","unstructured":"Hobeika, E. et al. Testing gene function early in the B cell lineage in mb1-cre mice. Proc. Natl Acad. Sci. USA 103, 13789\u201313794 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1591_CR14","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1084\/jem.180.5.1955","volume":"180","author":"JJ Peschon","year":"1994","unstructured":"Peschon, J. J. et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J. Exp. Med. 180, 1955\u20131960 (1994).","journal-title":"J. Exp. Med."},{"key":"1591_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nm.4062","volume":"22","author":"S Shojaee","year":"2016","unstructured":"Shojaee, S. et al. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nat. Med. 22, 379\u2013387 (2016).","journal-title":"Nat. Med."},{"key":"1591_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","volume":"560","author":"H Yao","year":"2018","unstructured":"Yao, H. et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature 560, 55\u201360 (2018).","journal-title":"Nature"},{"key":"1591_CR17","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","volume":"124","author":"J Irving","year":"2014","unstructured":"Irving, J. et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 124, 3420\u20133430 (2014).","journal-title":"Blood"},{"key":"1591_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1182\/blood-2017-03-769315","volume":"130","author":"V M\u00fcnch","year":"2017","unstructured":"M\u00fcnch, V. et al. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood 130, 643\u2013654 (2017).","journal-title":"Blood"},{"key":"1591_CR19","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/leu.2016.9","volume":"30","author":"S K\u00f6hrer","year":"2016","unstructured":"K\u00f6hrer, S. et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K\/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia 30, 1246\u20131254 (2016).","journal-title":"Leukemia"},{"key":"1591_CR20","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","volume":"29","author":"M Pfeifer","year":"2015","unstructured":"Pfeifer, M. et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 29, 1578\u20131586 (2015).","journal-title":"Leukemia"},{"key":"1591_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019000904","volume":"134","author":"F Vogiatzi","year":"2019","unstructured":"Vogiatzi, F. et al. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood 134, 713\u2013716 (2019).","journal-title":"Blood"},{"key":"1591_CR22","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1200\/JCO.2007.11.8166","volume":"25","author":"G Cario","year":"2007","unstructured":"Cario, G. et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J. Clin. Oncol. 25, 4813\u20134820 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1591_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"C Mullighan","year":"2009","unstructured":"Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New Engl. J. Med. 360, 470\u2013480 (2009).","journal-title":"New Engl. J. Med."},{"key":"1591_CR24","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","volume":"17","author":"MJ Borowitz","year":"2003","unstructured":"Borowitz, M. J. et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study. Leukemia 17, 1566\u20131572 (2003).","journal-title":"Leukemia"},{"key":"1591_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/pbc.22944","volume":"57","author":"WP Bowman","year":"2011","unstructured":"Bowman, W. P. et al. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children\u2019s Oncology Group Trial P9906. Pediatr. Blood Cancer 57, 569\u2013577 (2011).","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01591-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01591-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T19:04:28Z","timestamp":1670094268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01591-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-01591-z","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: M.B. received consulting fees from PRMA, research funding from Amgen, honoraria from Novartis, Pfizer, and Amgen and was an advisory board member for Incyte and Amgen. D.M.S. was an advisory board member for Bayer, SOBI and Jazz Pharmaceuticals and received research funding from OSE Pharmaceuticals. M.S. received research funding from Shire, and from Servier, as well as fees for Advisory Board functions from Jazzpharma, and Servier. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}